关于公司首次公开发行股票部分募投项目结项 并将节余募集资金永久补充流动资金的公告 证券代码：300938 证券简称：信测标准 公告编号：2023-127 深圳信测标准技术服务股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳信测标准技术服务股份有限公司（以下简称"公司"、"信测标准"） 于 2023 年 8 月 29 日召开了第四届董事会第二十次会议、第四届监事会第十九次 会议，审议通过了《关于公司首次公开发行股票部分募投项目结项并将节余募集 资金永久补充流动资金的议案》，同意公司将首次公开发行股票募投项目"迁扩 建华东检测基地项目"和"广州检测基地汽车材料与零部件检测平台建设项目" 结项，并将节余募集资金 1698.06 万元（含现金管理取得的理财收益及活期利息 收入，具体金额以资金转出当日银行结算余额为准）永久补充流动资金，用于公 司生产经营活动。 公司对募集资金采取了专户存储制度，设立了相关募集资金专项账户。募集 资金到账后，已全部存放于该募集资金专项账户内，并与保荐机构、存放募集资 金的银行签署了募集资金监管协议。 二、募集资金投资项目 ...

证券代码：300938 证券简称：信测标准 公告编号：2023-125 深圳信测标准技术服务股份有限公司 独立董事关于公司控股股东及其他关联方占用公司资金 和公司对外担保情况的专项说明和独立意见 根据中国证监会《上市公司独立董事规则》、《上市公司监管指引第 8 号—— 上市公司资金往来、对外担保的监管要求》、《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等有关规定，我们作为独立董事，就 2023 年半年度控股股东及其他关联方资金占用情况和公司对外担保情况进行了 认真的核查，并发表如下专项说明和独立意见： 一、关联方资金往来情况 报告期内，公司不存在控股股东及其他关联方违规占用公司资金的情形，亦 不存在以前年度发生并延续到报告期的控股股东及其他关联方违规占用公司资 金的情况。 独立董事： 张 敏（签字）： 陈若华（签字）： 吴华亮（签字）： 年 月 日 二、公司对外担保情况 报告期内，公司及其控股子公司不存在为股东、股东的控股子公司、股东的 附属企业及其他关联方、任何非法人单位或个人提供担保的情况；也不存在以前 年度累计至报告期违规对外担保情况。 （此页无正文，为《深圳信测标准技术 ...

证券代码：300938 证券简称：信测标准 公告编号：2023-121 深圳信测标准技术服务股份有限公司 第四届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、深圳信测标准技术服务股份有限公司（以下简称"公司"）第四届董事会 第二十次会议于 2023 年 8 月 18 日以网络、电话、专人送达等方式发出通知， 2023 年 8 月 29 日在公司会议室以现场及通讯的方式召开。 2、本次董事会应到董事 9 人，实际出席会议董事 9 人，列席监事 3 人。 3、本次会议由董事长吕杰中主持，董事、监事列席。会议召开和表决程序 符合有关法律、法规、规章和《公司章程》的规定。经各位董事认真审议，会议 形成了如下决议： 二、董事会会议审议情况 1、本次会议审议通过了《关于公司<2023 年半年度报告>全文及其摘要的议 案》 公司《2023 年半年度报告》及《2023 年半年度报告摘要》的编制程序符合 法律法规和中国证监会、深圳证券交易所的有关规定，报告内容真实、准确、完 整地反映了公司的实际情况，不存在任何虚假记载、 ...

一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于防 | 是 | | 止关联方占用公司资源的制度、募集资金管理制度、内控 | | | 制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 2 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4.公司治理督导情况 | | | （1）列席公司股东大会次数 | 未出席，已阅会议文件 | | （2）列席公司董事会次数 | 未出席，已阅会议文件 | | （3）列席公司监事会次数 | 未出席，已阅会议文件 | | 5.现场检查情况 | | | （1）现场检查次数 | 0，计划下半年进行现 | | | 场检查 | | （2）现场检查报告是否按照本所规定报送 | ...

单位：万元 深圳信测标准技术服务股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 注：①表中非经营性占用部分，关联方范围依照《创业板上市规则》确定。②无控股股东、实际控制人的公司，存在第一大股东或第一大股东关联人非经营性占用资金的，也应填写本表 非经营性占用部分。 | | | 占用方与上 | | 年半年 2023 | 2023 年半年 | 2023 年半 | 年半年 2023 | 年半年 2023 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 市公司的关 | 上市公司核算 | 度期初占用资 | 度占用累计发 | 年度占用 | 度偿还累计发 | 度期末占用资 | 占用形 | | | 非经营性资金占用 | 资金占用方名称 | | 的会计科目 | | 生金额（不含 | 资金的利 | | | 成原因 | 占用性质 | | | | 联关系 | | 金余额 | | | 生金额 | 金余额 | | | | | | | | | 利息） | 息（如有） | | | | | | 控股股东、 ...

证券代码：300938 证券简称：信测标准 公告编号：2023-126 深圳信测标准技术服务股份有限公司 独立董事关于第四届董事会第二十次会议 相关事项的独立意见 二、关于公司首次公开发行股票部分募投项目结项并将节余募集资金永久 补充流动资金的独立意见 （以下无正文） （本页无正文，为《深圳信测标准技术服务股份有限公司独立董事关于第四届董 事会第二十次会议相关事项的独立意见》签署页） 独立董事签名： 经核查，我们认为： 公司"迁扩建华东检测基地项目"和"广州检测基地汽车材料与零部件检测 平台建设项目"已达到预定可使用状态，公司本次部分募集资金投资项目结项并 将节余募集资金永久补充流动资金符合公司实际经营的需要和长远发展规划，有 利于提高资金使用效率，不存在损害公司及全体股东、特别是中小股东利益的情 形，亦不存在违规使用募集资金的情形。公司本次部分募集资金投资项目结项并 将节余募集资金永久补充流动资金履行了必要的决策程序，符合《深圳证券交易 所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等相关规范性文件及《公司章程》的规定。公司独立董 事一致同意本次部分募集 ...

三、本批复自同意注册之日起 12个月内有效。 四、自同意注册之日起至本次发行结束前,你公司如发生重 中国证券监督管理委员会收到深圳证券交易所报送的关于你 公司向不特定对象发行可转换公司债券的审核意见及你公司注册 申请文件。根据《中华人民共和国证券法》《中华人民共和国公司 法》《国务院办公厅关于贯彻实施修订后的证券法有关工作的通 知》(国办发〔2020〕5 号 ) 和《上市公司证券发行注册管理办法》 (证监会令第 206号）等有关规定,经审阅深圳证券交易所审核 意见及你公司注册申请文件,现批复如下: 一、同意你公司向不特定对象发行可转换公司债券的注册申 请。 二、你公司本次发行应严格按照报送深圳证券交易所的申报 文件和发行方案实施。 中国证券监督管理委员会 证监许可〔2023〕1895 号 关于同意深圳信测标准技术服务股份有限公司 向不特定对象发行可转换公司债券注册的批复 深圳信测标准技术服务股份有限公司: 2023 8 21 ...

Financial Performance - The company's revenue for Q1 2023 was ¥150,412,635.18, representing a 30.69% increase compared to ¥115,093,706.41 in the same period last year[5] - Net profit attributable to shareholders was ¥31,481,270.57, up 40.69% from ¥22,377,006.12 year-on-year[5] - Basic earnings per share rose to ¥0.2845, a 44.27% increase from ¥0.1972 in the same period last year[5] - The net increase in cash and cash equivalents was ¥47,424,249.51, reflecting a 640.58% rise from ¥6,403,691.27 in the same period last year[9] - The net profit for Q1 2023 reached CNY 34,403,384.90, up 50.8% from CNY 22,839,235.93 in Q1 2022[19] - The operating profit for the current period was CNY 39,645,054.35, an increase of 48.8% compared to CNY 26,643,314.77 in the previous year[19] Cash Flow - The net cash flow from operating activities increased by 42.30% to ¥29,781,326.30, compared to ¥20,928,814.72 in the previous year[5] - The net cash flow from operating activities was CNY 29,781,326.30, which is a 42.3% increase from CNY 20,928,814.72 in the same quarter last year[21] - The net cash flow from investment activities was 32,122,667.06 CNY, compared to a negative cash flow of 9,411,841.78 CNY in the previous period[22] - The net cash flow from financing activities was -14,394,651.50 CNY, a decline from -5,088,375.40 CNY in the previous period[22] - The cash inflow from financing activities was 750,000.00 CNY, all from minority shareholders' investments[22] - The cash outflow for debt repayment was 8,000,000.00 CNY, indicating ongoing financial obligations[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,494,604,648.12, a 1.54% increase from ¥1,471,901,040.15 at the end of the previous year[5] - The total current liabilities decreased to CNY 176,928,713.89 from CNY 189,441,786.65, a reduction of approximately 6.7%[15] - The company's total liabilities decreased to CNY 260,890,246.44 from CNY 278,519,458.65, a decline of approximately 6.3%[15] - The total equity attributable to shareholders increased by 3.32% to ¥1,163,875,628.82 from ¥1,126,464,922.97 at the end of the previous year[5] - The total equity attributable to shareholders of the parent company increased to CNY 1,163,875,628.82, up from CNY 1,126,464,922.97[16] Inventory and Receivables - Accounts receivable rose to CNY 217,359,878.84, up from CNY 190,733,998.23, indicating an increase of about 13.9%[14] - The inventory balance increased to CNY 55,270,128.86 from CNY 51,700,426.32, representing an increase of about 6.5%[14] Research and Development - Research and development expenses for the quarter were CNY 12,995,897.97, an increase of 22.5% from CNY 10,603,620.31 in the previous year[17] Other Information - The company had a total of 5,679 ordinary shareholders at the end of the reporting period[11] - There are no new product developments or market expansion strategies mentioned in the provided documents[13] - The company's first-quarter report was not audited[23]

信测标准投资者关系活动记录表 证券代码：300938 证券简称：信测标准 深圳信测标准技术服务股份有限公司 投资者关系活动记录表 投资者关系活动 类别 特定对象调研 □分析师会议 媒体采访 业绩说明会 □新闻发布会 □路演活动 现场参观 □其他 参与单位名称及 姓名 信测标准 2022 年度业绩说明会采用网络远程方式进行，面向全 体投资者 时间 2023 年 4 月 14 日 15:00-16:00 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云 访谈"栏目 上市公司接待人 员姓名 主持人：信测标准 董事长：吕杰中 董秘：蔡大贵 财务总监：黄光欣 独立董事：张敏 投资者关系活动 主要内容介绍 问题 1.公司 2022 年经营情况怎么样？ 答：2022 年度公司紧密围绕宏观经济、市场动态和客户需 求变化，不断加强行业互动和产业协同发展，积极应对克服宏 观因素带来的不利影响，较好地完成了各项业绩指标。2022 年 公司全年实现营业收入 54,510.87 万元，较去年同期增长 38.1 1%；实现归属母公司股东的净利润 11,804.88 万元，较去年同 期增长 47.46 ...

Financial Performance - The company's operating revenue for 2022 was RMB 545,108,653.48, representing a 38.11% increase compared to RMB 394,704,752.61 in 2021[25]. - The net profit attributable to shareholders for 2022 was RMB 118,048,837.87, up 47.46% from RMB 80,055,681.76 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was RMB 106,340,068.69, reflecting a 58.89% increase from RMB 66,928,326.35 in 2021[25]. - The net cash flow from operating activities reached RMB 173,531,739.54, a significant increase of 70.46% compared to RMB 101,799,333.29 in 2021[25]. - The total assets at the end of 2022 amounted to RMB 1,471,901,040.15, which is a 10.49% increase from RMB 1,332,120,549.85 at the end of 2021[25]. - The net assets attributable to shareholders increased to RMB 1,126,464,922.97, marking an 11.01% rise from RMB 1,014,722,940.92 in the previous year[25]. - The basic earnings per share for 2022 was RMB 1.0625, up 43.81% from RMB 0.7388 in 2021[25]. - The diluted earnings per share was RMB 1.0548, representing a 42.77% increase from RMB 0.7388 in the previous year[25]. - The weighted average return on equity for 2022 was 11.03%, an increase of 2.49 percentage points from 8.54% in 2021[25]. - The company reported a total revenue of 1,024 million in 2021, showing a significant increase from 470.2 million in 2019, representing a growth of approximately 117.1%[169]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% year-over-year growth[174]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 3 RMB per 10 shares to all shareholders, based on a total of 113,790,200 shares[4]. - The board of directors has approved a profit distribution plan, with no bonus shares to be issued[4]. - The board of directors has approved a dividend payout of 0.5 RMB per share, reflecting a commitment to returning value to shareholders[174]. Risk Management and Strategic Development - The company emphasizes the importance of risk awareness regarding future strategic developments and projections[4]. - The management discussion section outlines potential risks and countermeasures for future development[4]. Market and Industry Insights - The Chinese inspection and testing market size reached ¥4,090 billion in 2021, growing by ¥504 billion or 14.05% compared to 2020[40]. - The number of inspection reports issued by Chinese testing institutions reached 684 million in 2021, reflecting a year-on-year growth of 20.58%[42]. - The number of testing institutions in China increased to 51,949 by the end of 2021, representing a growth of 6.19%[42]. - The revenue of scale above testing institutions in 2021 was ¥3,228.30 billion, with a year-on-year increase of 16.37%[43]. - The global inspection and testing market is projected to maintain a compound annual growth rate of over 9%[38]. Research and Development - The company holds 281 patents, significantly higher than the industry average of 1.78 patents per institution[49]. - The company has established 8 laboratories in major cities, enhancing its service radius and efficiency[49]. - The company is currently developing a human weight static load testing machine, aiming to achieve a practical new patent to enhance testing quality and efficiency[103]. - The company is developing a wedge-shaped probe device for measuring mechanical hazards in shredders, aiming to enhance testing quality and efficiency[106]. - The company has completed the development of several new products, including a lithium battery explosion-proof device and a pneumatic wedge device, enhancing market competitiveness[110]. - The number of R&D personnel increased by 13.40% from 194 in 2021 to 220 in 2022, with R&D personnel accounting for 15.55% of the total workforce[111]. - R&D investment amounted to ¥47,775,078.41 in 2022, representing 8.76% of operating revenue, an increase from 7.89% in 2021[111]. Operational Efficiency and Cost Management - The company has successfully reduced operational costs by 5% through improved supply chain management practices[182]. - The company aims to launch three new products in 2023, which are anticipated to contribute an additional 200 million RMB in revenue[188]. - The company has set a target to reduce operational costs by 15% through digital transformation initiatives[188]. Governance and Compliance - The company maintained a robust governance structure, holding 13 board meetings and 12 supervisory meetings in 2022, ensuring compliance with regulations[152][154]. - The company reported a complete independence in assets, personnel, finance, and operations from its controlling shareholders, ensuring a fully operational business system[159]. - The company strictly followed information disclosure regulations, ensuring timely and accurate communication of significant operational matters[156]. - The company has established a comprehensive internal control system to enhance governance and operational efficiency[149]. Future Outlook and Strategic Goals - The company provided a positive outlook for 2023, projecting a revenue growth of 25% based on new product launches and market expansion strategies[188]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[188]. - The company aims to achieve a break-even point in new business areas such as health and environmental testing while ensuring the successful implementation of annual targets[137]. - The company will continue to optimize its service network and expand production capacity, particularly through the construction of the Central China dual-use testing base and projects in the new energy vehicle sector[140].